Corcept Therapeutics Incorporated (CORT)
Corcept Therapeutics: Recent Relacorilant Rejection Aside, A Good News Story For Investors
Corcept Therapeutics maintains a Buy rating, supported by robust revenue growth, pipeline progress, and strong management execution. Relacorilant's FDA approval in ovarian cancer and likely approval in Cushing's syndrome could drive CORT revenues above $3 billion annually by decade's end. 2026 revenue guidance of $950M–$1.05B reflects >30% YoY growth, with minimal impact expected from generic competition due to pipeline innovation.
Corcept Resubmits NDA for Relacorilant in Cushing's Syndrome
CORT resubmits relacorilant NDA for Cushing's syndrome, with updated analyses and data from multiple clinical studies supporting the filing.
CORT Stock Rises 42% in a Month: Here's What You Should Know
Corcept shares surge 42% in a month as relacorilant advances in Cushing's syndrome and Lifyorli approval to expand the company's revenue base.
CORT to Resubmit NDA for Relacorilant in Cushing's Syndrome, Stock Up
Corcept stock jumps after the company announces plans to resubmit relacorilant's NDA for treating Cushing's syndrome.
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade
The consensus price target hints at a 43.3% upside potential for Corcept (CORT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Will Korlym Continue to Aid CORT's Growth in 2026 After a Strong Q1?
Corcept raises 2026 revenue guidance after strong Korlym Q1 performance. New launches and pipeline progress may diversify future growth.
Corcept: 'Strong Buy' On Lifyorli FDA Approval And ALS Phase 3 Advancement
Corcept Therapeutics Incorporated remains a Strong Buy following early FDA approval of Lyforli [relacorilant] plus nab-paclitaxel for platinum-resistant ovarian cancer [PROC]. The company expects further upside from European approval, additional oncology indications, and a triple-combo study with Avastin, with key data and decisions anticipated by year-end. Phase 2 data for dazucorilant in ALS showed significant 1- and 2-year survival benefits, supporting a planned phase 3 study targeting overall survival as a primary endpoint.
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Corcept Therapeutics Incorporated (CORT) Q1 2026 Earnings Call Transcript
Corcept Therapeutics (CORT) Reports Q1 Loss, Misses Revenue Estimates
Corcept Therapeutics (CORT) came out with a quarterly loss of $0.3 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.17 per share a year ago.
Corcept Gains FDA Approval In Ovarian Cancer (Rating Upgrade)
Corcept Therapeutics Incorporated receives early FDA approval for Lifyorli (relacorilant) in platinum-resistant ovarian cancer, transforming its investment narrative. Lifyorli demonstrated a 35% reduction in risk of death and strong tolerability, positioning CORT as a new oncology leader in ovarian cancer. Analyst consensus sees Lifyorli's growth offsetting Korlym's decline, with 2026 sales guidance at $900M–$1B and potential blockbuster expansion.
CORT Rises on FDA Nod to Lifyorli in Platinum-Resistant Ovarian Cancer
Corcept jumps after FDA approves Lifyorli combo for platinum-resistant ovarian cancer, marking the first-of-its-kind treatment.
Why Is Corcept (CORT) Up 11.7% Since Last Earnings Report?
Corcept (CORT) reported earnings 30 days ago. What's next for the stock?
